Showing results (991-1000 of 1,027) with videos related to

Sort By:
Pageof 103
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infectionYueh-Ming Loo, David M Owen, Kui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Journal of the American Society of Nephrology : JASN|March 5, 2016
Polymorphisms in α-Defensin-Encoding DEFA1A3 Associate with Urinary Tract Infection Risk in Children with Vesicoureteral RefluxAndrew L Schwaderer, Huanyu Wang, SungHwan Kim, et al.
Journal of Dual Diagnosis|December 2, 2024
Problematic Substance Use in Depressed Youth: Associations with Suicidal Ideation and Suicide Attempt HistoryGabrielle M Armstrong, Jacey L Anderberg, April R Gorman, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Journal of Attention Disorders|July 25, 2025
ADHD in Youth With Major Depressive Disorder in the Texas Youth Depression and Suicide Research Network (TX-YDSRN): Clinical Correlates and ModeratorsBlake M Upshaw, Samuel D Spencer, Caitlin M Pinciotti, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitorsRima S Al-awar, James E Ray, Kyle A Hecker, et al.
Journal of Medicinal Chemistry|November 8, 2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-LinkersStephen J Gregson, Luke A Masterson, Binqing Wei, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
Pageof 103